IL18 and cancer: These results show that higher NLRP3 inflammasome (NLRP3/IL-18/IL-1β/ASC) expression in cancer tissues results in poor OS in LSCC patients compared to lower NLRP3 inflammasome (NLRP3/IL-18/IL-1β/ASC) expression.